INDV Stock Forecast & Price Target

Indivior Pharmaceuticals Inc. has demonstrated solid growth potential, as evidenced by the 8% increase in patients on its Sublocade treatment, reaching approximately 171,500 in the third quarter of 2025, and a notable 11% increase in the number of prescribers. The company has raised its guidance for worldwide sales of Sublocade to $825 million-$845 million, reflecting an anticipated annual growth rate of approximately 10% at the midpoint, further supported by a 15% increase in sales for the product in the same quarter. Furthermore, a positive outlook for continued category expansion in the long-acting injectable opioid use disorder market suggests that Sublocade could achieve peak sales potential in the range of $1.5 billion to $2.0 billion, contributing to favorable long-term EBITDA growth and justifying a higher valuation multiple.

Indivior Pharmaceuticals is experiencing a significant reduction in its market footprint for Sublocade, with commercial support decreasing from approximately 40 countries to only 4, which raises concerns about future revenue generation. Additionally, the discontinuation of commercial support for Opvee suggests a lack of strategic alignment and could further hinder potential revenue growth. Consensus projections indicate a revenue decline of around 6.5% in 2026 due to portfolio simplification efforts in 2025, casting a shadow on the outlook for financial performance despite possible improvements in EBITDA margins from guidance.